Utilities and technology are two bright spots in U.S. stocks, says Bill Stone, chief investment strategist at PNC Asset Management.» Read More
The "Squawk on the Street" news team reports on today's top business headlines, including a look at June, as the markets kick off another month; and a look at how positive news on several promising cancer drugs are impacting big pharma stocks.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
The bull case for stocks remains intact, despite their worst one-day declines in about seven weeks, Thomas Lee, chief U.S. equity strategist at JPMorgan, tells CNBC.
Michael Ryan, UBS Wealth Management, provides a preview of Friday's jobs report. And, Larry Bossidy, former Honeywell chairman & CEO explains why investors need to make the distinction between Fed "tapering" and "tightening."
Lawrence Bossidy, former Honeywell chairman& CEO, provides his views on when and how the Fed's tapering program should begin.
Michelle Girard, RBS chief economist, and Nariman Behravesh, IHS chief economist, weigh in on how the markets are likely to react to the Fed's tapering program and provide a preview of Friday's employment report.
Thomas Lee, JPMorgan chief U.S. equity strategist, explains why the market's "underlying bullish story" is still sound despite rising rates.
CNBC's Ross Westgate tells you what the markets will be watching as we approach the start of trading in the U.S.
Paul Donovan, Global Economist, Managing Director at UBS says there is a risk of a ECB rate cut due to the disappointing economic data out of Europe. However he says it's not a likelihood since there isn't much room left to maneuver on policy.
Junk bond issuance is at record highs this year — and thus at the greatest danger should yields keep rising.
Discussing the big sell off that occurred in the markets today just 15 minutes before the close, with CNBC Contributor Jack Bouroudjian and Jim Lacamp, UBS.
Mad Money host Jim Cramer test drives Tesla's Model S, and discusses his thoughts on the stock.
Mad Money host Jim Cramer discusses TearLab's rally from $4 at the beginning of the year to $10 as of today, and why this stock could serve as a speculative play for your portfolio.
Occidental Petroleum is currently in the middle of a multi-stage strategic review. Mad Money host Jim Cramer offers insight on a potential break up for the company.
Celldex Therapeutics has been on a tear lately, explains Mad Money host Jim Cramer. The company is working on a game-changing anti-cancer platform.
Mad Money host Jim Cramer dissects the trading action in May, and how to prepare your portfolio for the worst.
Does your insurance cover objects falling from outer space? CNBC's Jane Wells has the details of a giant asteroid making its closest pass to Earth in 200 years.
How to play bond yields if they spike too quickly, and today's top 3 trades, with the "Fast Money" traders.
Should investors take on the "buy on the dip" mentality right now? Ron Weiner, RDM Financial; Eric Green, Penn Capital Management; Chad Morganlander, Stifel Nicolaus; and Stephanie Link, TheStreet, discuss.
In the past week, mutual fund inflows came in at the lowest levels of the year. CNBC's Jeff Cox and Rich Peterson, Standard & Poor's Capital IQ, discuss what this signals.